( 您好!臺灣時間:2023/10/05 11:26
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::


研究生(外文):Hsin-Yu Yu
論文名稱(外文):The assessment of survival risk and duration of initial treatment with determining factors among patients with Hepatocellular Carcinoma
指導教授(外文):Shang-Jyh ChiouChien-Hung Chen
口試委員(外文):Kuan-Chia LinYa-Hsin Li
外文關鍵詞:Hepatocellular carcinomaduration of initial treatmentKaplan-Meier survival analysis
  • 被引用被引用:2
  • 點閱點閱:273
  • 評分評分:
  • 下載下載:52
  • 收藏至我的研究室書目清單書目收藏:0
本研究屬回溯性研究,運用某醫學中心癌症登記資料,針對2011-2013年新診斷且接受首次治療的1623位肝癌病人,以Cox proportional hazard model 及K-M存活分析,探討BCLC分期、治療方式、首次治療時間與存活之關係。
研究結果顯示C型肝炎、胎兒蛋白、BCLC C期、接受局部治療為影響治療時程之相關因子。在BCLC分期、治療方式與首次治療時間之存活分析,無論將癌症分期、治療方式單獨或合併與首次治療時間進行分析,研究結果絕大多數為延遲治療不會影響平均存活月數,少部分顯示延遲治療會影響平均存活月數,且發現被歸為延遲治療組之存活月數高於非延遲治療組。

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. In recent years, the treatments of HCC have more progress, but there is no conclusive definition for the duration of initial treatment in delay. The relationship between the duration of initial treatment and survival of HCC is also not reaching the determination. The purpose of this study is to investigate the duration from the first time diagnosis to the first treatment among newly diagnosed HCC patients.
It was a retrospective study and we conducted the cancer registry database from a medical center during 2011-2013. The newly diagnosed HCC patients were 1629 cases remained after selection criteria. We used Cox proportional hazard model and Kaplan-Meier survival analysis to calculate the distribution of duration the initial diagnosis to the first time treatment and explore the relationship between the BCLC stagings, treatment and survival duration with determining factors.
Results from this study found that hepatitis C, AFP, BCLC stage C, and received topical remedy patients, were the impact factors associated with duration of initial treatment. Regarding the cancer stages, or treatment, we found that the delay in treatment was not significantly related with the survival months in most situations which either used stage or treatment separately or coincidently in the study groups. Only some results revealed that the delay in treatment was associated with the survival months while the survival months in the delayed treatment group was longer than in the non-delay treatment group.
We used the week period to divide the duration of initial treatment for the study purpose. The results showed that tumor stages and treatments were associated with the survival risk. In the meantime, hepatitis patients, the duration of treatment assessment, drug probe or the duration of treatment audit were the factors related to the duration of first time treatment. Due to the information in this database with limited observation period and sample size, the relationship between the survival risk and the duration of first time treatment was indeterminate for the further research to provide more evidence.

第一章 緒論 1
第一節 前言 1
第二節 研究目的 2
第二章 文獻探討 3
第一節 肝癌 3
第二節 首次治療時間 9
第三章 研究設計與方法 11
第一節 研究架構 11
第二節 研究設計 12
第四章 研究結果 15
第一節 肝癌病人之基本屬性 15
第二節 影響肝癌病人首次治療時間之相關因子 18
第三節 BCLC分期與首次治療時間之存活分析 21
第四節 治療方式與首次治療時間之存活分析 27
第五節 各BCLC分期治療方式與首次治療時間之存活分析 34
第五章 討論及建議 45
第六章 研究結論 49
參考文獻 51
陳星佑、吳岱穎、鄭企峰、郭冠良、陳建志 (2014)。腫瘤標記的臨床應用與發展。
臺灣公共衛生雜誌,33(4),352-359。doi: 10.6288/tjph201433103030
Brouha, X. D. R., Tromp, D. M., Hordijk, G.-J., Winnubst, J. A. M., & de Leeuw, J. R. J.
(2005). Oral and pharyngeal cancer: analysis of patient delay at different tumor stages. Head and Neck, 27(11), 939-945.
Bruix, J., Gores, G. J., & Mazzaferro, V. (2014). Hepatocellular carcinoma: clinical
frontiers and perspectives. Gut, 63(5), 844-855. doi: 10.1136/gutjnl-2013-306627
Bruix, J., & Sherman, M. (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53(3), 1020-1022. doi: 10.1002/hep.24199
Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S., . . . Guan, Z.
(2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind,
placebo-controlled trial. The Lancet Oncology, 10(1), 25-34. doi:10.1016/s1470-2045(08)70285-7
Cancer Registry, Medical Information Management Office, NTUH. (2015).
Dang-Tan, T., Trottier, H., Mery, L. S., Morrison, H. I., Barr, R. D., Greenberg, M. L.,
& Franco, E. L. (2008). Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatr Blood Cancer, 51(4), 468-474. doi: 10.1002/pbc.21600
Des Guetz, G., Nicolas, P., Perret, G.-Y., Morere, J.-F., & Uzzan, B. (2010). Does
delaying adjuvant chemotherapy after curative surgery for colorectal cancer
impair survival? A meta-analysis. European JournalOf Cancer, 46(6), 1049-1055. doi: 10.1016/j.ejca.2010.01.020
Dwivedi, A. K. (2012). An epidemiological study on delay in treatment initiation of
cancer patients. Health, 4(2), 66-79. doi: 10.4236/health.2012.42012
Hansen, R. P., Vedsted, P., Sokolowski, I., Søndergaard, J., & Olesen, F. (2011). Time
intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients. BMC Health Services Research, 11, 284. doi: 10.1186/1472-6963-11-284
Harirchi, I., Ghaemmaghami, F., Karbakhsh, M., Moghimi, R., & Mazaherie, H.
(2005). Patient delay in women presenting with advanced breast cancer: an Iranian study. Public Health, 119(10), 885-891. doi: 10.1016/j.puhe.2004.11.005
Hershman, D. L., Wang, X., McBride, R., Jacobson, J. S., Grann, V. R., & Neugut, A.
I. (2006). Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. International Journal of Radiation Oncology, Biology, Physics, 65(5), 1353-1360.
Jassem, J., Ozmen, V., Bacanu, F., Drobniene, M., Eglitis, J., Lakshmaiah, K. C., . . .
Zaborek, P. (2014). Delays in diagnosis and treatment of breast cancer: a multinational analysis. European Journal of Public Health, 24(5), 761-767. doi: 10.1093/eurpub/ckt131
Llovet JM., Bruix J. (2012). Hepatocellular carcinoma. Lancet 379, 1245-1255. doi:
Macià, F., Pumarega, J., Gallén, M., & Porta, M. (2013). Time from (clinical or
certainty) diagnosis to treatment onset in cancer patients: the choice of diagnostic date strongly influences differences in therapeutic delay by tumor site and stage. Journal of Clinical Epidemiology, 66(8), 928-939. doi: 10.1016/j.jclinepi.2012.12.018
Macleod, U., Mitchell, E. D., Burgess, C., Macdonald, S., & Ramirez, A. J. (2009).
Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. British Journal of Cancer, 101(2), 92-101. doi: 10.1038/sj.bjc.6605398
Nikonova, A., Guirguis, H. R., Buckstein, R., & Cheung, M. C. (2015). Predictors of
delay in diagnosis and treatment in diffuse large B-cell lymphoma and impact on survival. British Journal Of Haematology, 168(4), 492-500. doi: 10.1111/bjh.13150
North, J. B., Blackford, F. J., Wall, D., Allen, J., Faint, S., Ware, R. S., & Rey-Conde,
T. (2013). Analysis of the causes and effects of delay before diagnosis using surgical mortality data. British Journal of Surgery, 100(3), 419-425. doi: 10.1002/bjs.8986
World Health Organization (2015). Cancer. Retrieved from
Radzikowska, E., Roszkowski-Śliż, K., & Głaz, P. (2012). The impact of timeliness of
care on survival in non-small cell lung cancer patients. Pneumonologia I Alergologia Polska, 80(5), 422-429.
Singal, A. G., Waljee, A. K., Patel, N., Chen, E. Y., Tiro, J. A., Marrero, J. A., & Yopp, A. C. (2013). Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. Journal of the National Comprehensive Cancer Network, 11(9), 1101-1108.
The NHS Cancer Plan. (2000).
Tomlinson, C., Wong, C., Au, H.-J., & Schiller, D. (2012). Factors associated with
delays to medical assessment and diagnosis for patients with colorectal cancer.
Canadian Family Physician Médecin De Famille Canadien, 58(9), 495-501.
van Harten, M. C., Hoebers, F. J. P., Kross, K. W., van Werkhoven, E. D., van den
Brekel, M. W. M., & van Dijk, B. A. C. (2015). Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival. Oral Oncology, 51(3), 272-278. doi: 10.1016/j.oraloncology.2014.12.003

第一頁 上一頁 下一頁 最後一頁 top